Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a US-based speciality pharmaceutical company, announced on Monday that has signed a national co-promotion agreement with Verity Pharmaceuticals International Ltd, a Canada-based speciality pharmaceutical company, to support Cumberland's new Sancuso oncology support product.
According to a co-promotion partnership, Verity is to feature Sancuso across the United States via its established oncology commercial organisation and customer network.
Sancuso, the first and only FDA-approved prescription patch, is intended for the prevention of nausea and vomiting in patients receiving certain types of chemotherapy treatment.
Under the terms of the contract, Verity Pharmaceuticals is to promote Sancuso throughout most of the country via its national oncology sales organisation. Both firms will share in the incremental contribution margin resulting from Verity Pharmaceuticals' efforts.
Sanofi's Nexviadyme gets EU approval in Pompe disease
Ceruvia Lifesciences' synthetic psilocybin Phase two clinical trial receives US FDA approval
Ipsen agrees to acquire Epizyme
ImmuPharma reports Avion seeking final FDA guidance ahead of Phase 3 trial of Lupuzor
Daewoong Pharmaceutical's IND for DWN12088 receives FDA approval for phase two clinical trial
Investigational Lenacapavir Receives Positive CHMP Opinion for People with Multi-Drug Resistant HIV